A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
1
Issued Date
2025-01-01
Resource Type
eISSN
22221751
Scopus ID
2-s2.0-105002219198
Journal Title
Emerging Microbes and Infections
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Emerging Microbes and Infections Vol.14 No.1 (2025)
Suggested Citation
Moodie Z., Li S.S., Giorgi E.E., Williams L.T.D., Dintwe O., Carpp L.N., Chen S., Seaton K.E., Sawant S.S., Zhang L., Heptinstall J., Liu S., Grunenberg N., Tomaka F., Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Ake J.A., Vasan S., Pantaleo G., Frank I., Baden L.R., Goepfert P.A., Keefer M., Chirenje M., Hosseinipour M.C., Mngadi K., Laher F., Garrett N., Bekker L.G., De Rosa S., Andersen-Nissen E., Kublin J.G., Lu S., Gilbert P.B., Gray G.E., Corey L., McElrath M.J., Tomaras G.D. A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials. Emerging Microbes and Infections Vol.14 No.1 (2025). doi:10.1080/22221751.2025.2485317 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/109554
Title
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Author(s)
Moodie Z.
Li S.S.
Giorgi E.E.
Williams L.T.D.
Dintwe O.
Carpp L.N.
Chen S.
Seaton K.E.
Sawant S.S.
Zhang L.
Heptinstall J.
Liu S.
Grunenberg N.
Tomaka F.
Rerks-Ngarm S.
Pitisuttithum P.
Nitayaphan S.
Ake J.A.
Vasan S.
Pantaleo G.
Frank I.
Baden L.R.
Goepfert P.A.
Keefer M.
Chirenje M.
Hosseinipour M.C.
Mngadi K.
Laher F.
Garrett N.
Bekker L.G.
De Rosa S.
Andersen-Nissen E.
Kublin J.G.
Lu S.
Gilbert P.B.
Gray G.E.
Corey L.
McElrath M.J.
Tomaras G.D.
Li S.S.
Giorgi E.E.
Williams L.T.D.
Dintwe O.
Carpp L.N.
Chen S.
Seaton K.E.
Sawant S.S.
Zhang L.
Heptinstall J.
Liu S.
Grunenberg N.
Tomaka F.
Rerks-Ngarm S.
Pitisuttithum P.
Nitayaphan S.
Ake J.A.
Vasan S.
Pantaleo G.
Frank I.
Baden L.R.
Goepfert P.A.
Keefer M.
Chirenje M.
Hosseinipour M.C.
Mngadi K.
Laher F.
Garrett N.
Bekker L.G.
De Rosa S.
Andersen-Nissen E.
Kublin J.G.
Lu S.
Gilbert P.B.
Gray G.E.
Corey L.
McElrath M.J.
Tomaras G.D.
Author's Affiliation
Fred Hutchinson Cancer Center
Faculty of Tropical Medicine, Mahidol University
University of the Witwatersrand Faculty of Health Sciences
UNC Project-Malawi
University of Zimbabwe
South African Medical Research Council
University of Rochester Medical Center
Centre Hospitalier Universitaire Vaudois
UNC School of Medicine
The Aurum Institute
Brigham and Women's Hospital
Thailand Ministry of Public Health
University of Washington
HJF
Walter Reed Army Institute of Research
Johnson & Johnson
University of KwaZulu-Natal
Royal Thai Army
Duke University School of Medicine
UAB Department of Medicine
University of Pennsylvania Perelman School of Medicine
University of Massachusetts Chan Medical School
University of Cape Town
Worcester HIV Vaccine
Cape Town
Faculty of Tropical Medicine, Mahidol University
University of the Witwatersrand Faculty of Health Sciences
UNC Project-Malawi
University of Zimbabwe
South African Medical Research Council
University of Rochester Medical Center
Centre Hospitalier Universitaire Vaudois
UNC School of Medicine
The Aurum Institute
Brigham and Women's Hospital
Thailand Ministry of Public Health
University of Washington
HJF
Walter Reed Army Institute of Research
Johnson & Johnson
University of KwaZulu-Natal
Royal Thai Army
Duke University School of Medicine
UAB Department of Medicine
University of Pennsylvania Perelman School of Medicine
University of Massachusetts Chan Medical School
University of Cape Town
Worcester HIV Vaccine
Cape Town
Corresponding Author(s)
Other Contributor(s)
Abstract
Developing an effective HIV vaccine is a momentous challenge. An exceptionally wide range of candidate HIV vaccines have been tested, yet many were poorly immunogenic, and of the select few that advanced into efficacy trials, only one demonstrated any efficacy. Here we report the results of the largest-scale cross-protocol immunogenicity comparison to date: 13 HIV vaccine trials (including 36 vaccine regimens) conducted across nine countries worldwide, strengthened by standardized trial designs, validated assays in centralized laboratories, and harmonized immunogenicity endpoints–providing an objective approach to identify the HIV vaccine candidate(s) with the best immunogenicity. A polyvalent DNA prime + protein boost regimen (HVTN 124) including Env immunogens of four subtypes, matched between prime and boost, achieved the best anti-V1V2 antibody responses by a large margin and also induced high CD4+ T-cell responses–two key immune responses implicated in HIV vaccine protection. Our results provide strong support to test this promising HIV vaccine design in more advanced phase clinical trials and will also guide the future design of additional HIV vaccines. Trial registration:ClinicalTrials.gov identifier: NCT01799954. Trial registration:ClinicalTrials.gov identifier: NCT02109354. Trial registration:ClinicalTrials.gov identifier: NCT02404311. Trial registration:ClinicalTrials.gov identifier: NCT02207920. Trial registration:ClinicalTrials.gov identifier: NCT02296541. Trial registration:ClinicalTrials.gov identifier: NCT03284710. Trial registration:ClinicalTrials.gov identifier: NCT02915016. Trial registration:ClinicalTrials.gov identifier: NCT02997969. Trial registration:ClinicalTrials.gov identifier: NCT03122223. Trial registration:ClinicalTrials.gov identifier: NCT03409276. Trial registration:ClinicalTrials.gov identifier: NCT02968849. Trial registration:ClinicalTrials.gov identifier: NCT03060629. Trial registration:ClinicalTrials.gov identifier: NCT00223080.